Paradigm Biopharmaceuticals (PBIGF) Stock Statistics & Valuation Metrics

Paradigm Biopharmaceuticals has a market cap or net worth of $111.37M. The enterprise value is $48.90.

Paradigm Biopharmaceuticals has 625,833,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Paradigm Biopharmaceuticals’s return on equity (ROE) is -16.23 and return on invested capital (ROIC) is -484.07%.

The current PE Ratio of Paradigm Biopharmaceuticals is ―. Paradigm Biopharmaceuticals’s PEG ratio is -0.00727.

In the last 12 months, Paradigm Biopharmaceuticals had revenue of 80.15K and earned -56.33M in profits. Earnings per share was -0.15.

In the last 12 months, operating cash flow was -43.69M and capital expenditures 43.69M, giving a free cash flow of 0.00 billion.

Paradigm Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Paradigm Biopharmaceuticals upcoming earnings date is Feb 24, 2027, TBA (Confirmed).

Paradigm Biopharmaceuticals as a current ratio of 1.10, with Debt / Equity ratio of 216.37%

In the past 12 months, Paradigm Biopharmaceuticals has paid -7.62M in taxes.

Paradigm Biopharmaceuticals EV to EBITDA ratio is -0.87, with an EV/FCF ratio of -1.22.

Paradigm Biopharmaceuticals has $15.44M in cash and marketable securities with $7.51M in debt, giving a net cash position of $7.93M billion.

Gross margin is -102.76%, with operating margin of -76246.47%, and net profit margin of -70282.28%.

The average price target for Paradigm Biopharmaceuticals is $0.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy